Prostate Cancer Diagnosis, Uro-Pathology Services Seeded By HealthTronics
This article was originally published in The Gray Sheet
Executive Summary
HealthTronics' access to an enhanced physician-customer base, via its purchase of Prime Medical, will help the firm add diagnostics to its core urology offerings next year
You may also be interested in...
HealthTronics Primes Prostate Therapy Business With $146 Mil. Merger
HealthTronics' nascent prostate disease segment will be fortified by the addition of Prime Medical's urology customer base, following a planned merger of the firms
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.